Charles River Laboratories International (CRL) reported Q4 non-GAAP earnings Wednesday of $2.66 per diluted share, up from $2.46 per share a year earlier.
Analysts polled by FactSet expected $2.53.
Revenue for the quarter ended Dec. 28 was $1 billion, compared with $1.01 billion a year earlier.
Analysts surveyed by FactSet expected $983.6 million.
The company expects full-year 2025 non-GAAP earnings of $9.10 to $9.60 per share. Analysts surveyed by FactSet expect $9.60 per share. The company expects a revenue decrease for 2025 of 7% to 4.5%. Analysts polled by FactSet expect $3.87 billion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.